358 related articles for article (PubMed ID: 31536991)
1. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
[TBL] [Abstract][Full Text] [Related]
2. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
Kim JY; Lee Y; Choe BH; Kang B
Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
[TBL] [Abstract][Full Text] [Related]
5. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
6. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
7. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
8. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
9. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
[TBL] [Abstract][Full Text] [Related]
10. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.
Hong SN; Hye Song J; Jin Kim S; Ha Park Y; Wan Choi C; Eun Kim J; Ran Kim E; Kyung Chang D; Kim YH
Inflamm Bowel Dis; 2024 Apr; 30(4):517-528. PubMed ID: 37260346
[TBL] [Abstract][Full Text] [Related]
11. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
12. Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease.
Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Andreou NP; Gazouli M; Koutroubakis IE
Int J Colorectal Dis; 2022 Mar; 37(3):639-646. PubMed ID: 35013823
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Treatment Outcomes and Serum Vitamin D Levels As Well As Infliximab Trough Concentration among Chinese Patients with Crohn's Disease.
Song X; Zhang H; Wang H; Li Z; Zhou X; Guo H
Gastroenterol Res Pract; 2023; 2023():6675401. PubMed ID: 37842203
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
15. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.
Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.
Moore C; Corbett G; Moss AC
J Crohns Colitis; 2016 May; 10(5):619-25. PubMed ID: 26763722
[TBL] [Abstract][Full Text] [Related]
17. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
[TBL] [Abstract][Full Text] [Related]
18. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
[TBL] [Abstract][Full Text] [Related]
20. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
